The biotechnology company Syngoi inaugurates its new facilities in the Science and Technology Park of Bizkaia.
March 8, 2023. Bizkaia.
The General Deputy of Bizkaia, Unai Rementeria Maiz, will preside over the inauguration in the presence of distinguished guests.
The inauguration ceremony took place on Wednesday, March 8 at 1:45 p.m. in the auditorium of the Science and Technology Park of Bizkaia, with the presence of the General Deputy of Bizkaia, Unai Rementeria Maiz, and important authorities, businessmen, scientists, investors and employees of the organization.
The press had a tour of the facilities on the day of the event, starting at 09h30 at Syngoi, where they had accessed to the different areas, including the laboratories where the optimized synthetic DNA for gene therapy to be produced by the company is being manufactured.
This is a relevant milestone for the Basque Country, since Syngoi has a cutting-edge technology, unique in the world to manufacture DNA, which vindicates the international biotechnological leadership of the territory, as well as the creation of highly qualified jobs.
Syngoi belongs to the portfolio of Columbus Venture Partners -a venture capital firm specialized in biotechnology-, which has founded leading companies such as Viralgen, Vivet Therapeutics, Highlight Therapeutics and Aura, among others.
About Syngoi Technologies
Biotech company dedicated to the production of optimized synthetic DNA for gene therapy. It is the only one in the industry to produce it in cGMP quality.
Syngoi produces covalently locked linear DNA to produce genes and has developed and patented a production method in a cell-free environment to synthesize optimized DNA containing nucleotides -natural and/or non-natural- as adapters.
This scalable process allows manufacturing under cGMP conditions, with competitive prices and significantly faster than the production of pDNA (plasmid DNA) and customizable, allowing to obtain a DNA tailored to the needs of customers with higher purity, adapted to the requirements of advanced gene therapies for the treatment of various diseases.
About Columbus Venture Partners
Is a Spanish venture capital investment manager founded in 2016 with a unique focus on business opportunities arising in the biotech and life sciences sector.
Columbus VP supports the most innovative science emerging in research centers and start-ups and accompanies it in its development until the final commercialization of new products and treatments that offer effective solutions to unmet medical needs.
Its team of professionals combines solid scientific, medical and business knowledge with extensive experience in establishing and investing in biotech companies.
It is distinguished by its transversal human vision in all its activities. It is worth mentioning the Columbus Foundation, the organization it has created so that children with rare and ultra-rare genetic diseases can have access to advanced therapies.
